Labcorp (LH) said Monday it has made available the Labcorp Plasma Complete, a circulating tumor DNA-based test for patients with advanced solid tumors.

The test detects genomic alterations across 521 genes, including biomarkers associated with FDA-approved treatments.

The liquid biopsy test allows oncologists to profile patients from blood samples and draw up personalized treatments, the healthcare company said.

LH shares were 0.1% higher in recent premarket activity.